EMSCULPT NEO,
does it really help with Reduced ultrasound-measured abdominal subcutaneous fat thickness and increased rectus abdominis thickness?
research showsThe grade is C. In the paper's 72-participant sham trial, 48 versus 24 were randomized and 40 versus 16 attended three months. Active treatment reduced subcutaneous fat by 28.3±5.4% (7.6±3.7 mm) and increased rectus thickness by 24.2±8.5% (2.3±0.9 mm); sham changes were at most 1.1% for fat and 0.9±2.0% for muscle. These are large imaging changes, but they are surrogate outcomes and the manufacturer-linked study had multiple reporting limitations, giving C with 50 points.
ads claimUltrasound-measured fat and rectus thickness genuinely changed. The trial did not establish weight loss, visceral-fat reduction, metabolic-disease treatment, greater strength, or back-pain relief.
Useful facts when choosing a product
- Both groups received three weekly abdominal sessions; sham energy was set to 5%.
- NCT04587986 was registered after primary completion, and paper enrollment of 72 (48/24) conflicts with registry actual enrollment of 67.
- The paper states, ‘No funding was received for this article’; the registry sponsor was BTL Industries Ltd.; and all three authors advised BTL.
What the research actually shows
Samuels JB, Katz B, and Weiss RA reported randomizing 72 participants, 48 versus 24. Treatment completion and the one-month visit included 67, 48 versus 19; three months included 56, 40 versus 16; six months included 28, 21 versus 7. Thus attrition was 16/72 (22.2%) at three months and 44/72 (61.1%) at six months. NCT04587986 was first submitted on October 6, 2020, after primary completion on June 16, 2020, and its actual enrollment of 67 conflicts with the paper's 72. The paper states, ‘No funding was received for this article’; the registry sponsor is BTL Industries Ltd.; and all three authors disclosed BTL medical-advisory roles.
Why this is classified as C (50)
Large sham-controlled imaging changes are capped by surrogate outcomes, manufacturer-only evidence, unreported allocation methods, attrition, and registry inconsistency, giving C with 50 points.
Counterpoint. C does not deny the ultrasound changes; it reflects uncertainty about durable patient benefit and independent replication.
Rejudgment record. Cross-check applied — We cross-checked randomized and follow-up denominators, outcomes, funding language, author disclosures, registry sponsor, and enrollment discrepancy against the article and NCT04587986.
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced abdominal subcutaneous-fat thickness | C | Active treatment showed −28.3% at three months with minimal sham change. |
| Increased rectus-abdominis thickness | C | Active treatment showed +24.2% versus +0.9% with sham at three months. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Samuels JB, Katz B, Weiss RA, 2022 | Randomized 2:1 low-energy sham-controlled trial; registered after primary completion | 67 | Paper states, ‘No funding was received for this article’; all three authors were BTL medical advisers; registry sponsor BTL Industries Ltd. | Ultrasound subcutaneous-fat and rectus-abdominis thickness | At three months, active fat −28.3±5.4% (−7.6±3.7 mm), muscle +24.2±8.5% (+2.3±0.9 mm); sham maximum mean fat change 1.1% and muscle +0.9±2.0% | Pivotal manufacturer-linked imaging-surrogate trial |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-14).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-14 · Corrections: none
Cite this verdict
[Chamgap] EMSCULPT NEO x abdominal fat reduction and rectus muscle thickening — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/emsculpt-neo-abdominal-fat-muscle-ultrasound/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.